Premium
Association of statin and nonsteroidal anti‐inflammatory drug use with prostate cancer outcomes: results from CaPSURE
Author(s) -
Katz Matthew S.,
Carroll Peter R.,
Cowan Janet E.,
Chan June M.,
D’Amico Anthony V.
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09232.x
Subject(s) - medicine , prostate cancer , hazard ratio , statin , oncology , prostatectomy , cancer , proportional hazards model , population , cancer registry , confidence interval , environmental health
Study Type – Prevalence (prospective cohort)
Level of Evidence 1b OBJECTIVE To determine whether 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) and nonsteroidal anti‐inflammatory drugs (NSAIDs) are associated with the risk of prostate cancer and improved survival in men with prostate cancer. PATIENTS AND METHODS We retrospectively examined the association between NSAID and statin use among 7042 men who underwent radical prostatectomy (RP, 4611) or radiotherapy (RT, 2431) for prostate cancer between 1990 and 2003 identified in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a primarily community‐based national prostate cancer registry. We compared clinical and sociodemographic variables by statin and NSAID use, using chi‐square tests and multinomial logistic regression. We examined associations between medications and comorbid illness with mortality using unadjusted and adjusted Cox proportional hazard models. RESULTS The median (range) follow‐up from treatment was 4 (0–16) years. In multivariate survival analysis, statin ‘ever‐use’ was associated with a reduced risk of all‐cause mortality (ACM) after RP (hazard ratio, HR, 0.35, 95% confidence interval, CI, 0.21–0.58) and RT (0.59, 0.37–0.94). NSAID ever‐use was also associated with a reduced risk of ACM after RP (HR 0.47, 95% CI 0.30–0.75) and RT (0.39, 0.25–0.59). CONCLUSIONS In a population of men with prostate cancer, statin and NSAID ever‐use were associated with a reduced risk of ACM. Our study highlights the importance of multidisciplinary survivorship care for men with prostate cancer.